Comprehensive AML Samples Collection

A Total of 77 bone marrow samples from AML patients and 72 control samples from healthy volunteers were collected from October 2019 to December 2021. A total of 5 AML patients presenting with high leukocyte counts consented to undergo leukapheresis to collect primary cells. Peripheral blood mononuclear cells (PBMC) from 2 healthy donors were extracted to detect the toxicity of drugs. The mononuclear cells were separated using a lymphocytes separation medium (MP biomedicals, Cat. No.S5019, USA) and erythrocytes were lysed with red blood cell lysis buffer (Biosharp, Cat. No. BL503A, China). Total RNA was isolated from samples using Trizol as described previously [12 (link)], and the complementary DNA was prepared for the detection of the target genes by Real-time quantitative Polymerase Chain Reaction (RT-qPCR). The primary cells were cultured in Roswell Park Memorial Institute 1640 medium (RPMI 1640, Gibco, USA) with 10% fetal bovine serum (FBS, Gibco, USA) and subsequently used in various experiments. The characterization of the patients is shown in Additional file 1: Table S1. The cases of AML at Zhongda Hospital Southeast University were used in this study after the acquisition of written informed consent, and by the tenets of the Declaration of Helsinki and approved by the Independent Ethics Committee for Clinical Research of Zhongda Hospital Southeast University.